PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer

In recent years, the deoxycytidine analogue gemcitabine (2′,2′,-difluorodeoxycytidine) has become the first-line chemotherapeutic agent for patients with pancreatic cancer. However, due to the intrinsic resistance of pancreatic cancer cells, gemcitabine-based chemotherapy yields limited disease cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wenbin, Zhu, Yue, Zhang, Kelin, Yu, Xianhuan, Lin, Haoming, Wu, Wenrui, Peng, Yaorong, Sun, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156657/
https://www.ncbi.nlm.nih.gov/pubmed/32123287
http://dx.doi.org/10.1038/s12276-020-0390-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156657/
https://www.ncbi.nlm.nih.gov/pubmed/32123287
http://dx.doi.org/10.1038/s12276-020-0390-4

Ejemplares similares